Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advances analyze observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://mitcht985ort6.is-blog.com/profile